15-Year Check-In: what happens after experimental cancer therapy?
NCT ID NCT00923026
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 22 times
Summary
This study does not offer new treatment. Instead, it follows about 1,150 people who previously received experimental cell or gene therapy for cancers like melanoma or neuroendocrine tumors. Participants will have yearly physical exams and blood tests for up to 15 years so doctors can track long-term safety and survival as required by the FDA.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.